

Short-Communication

Aloe vera supplementation improves cardiovascular risk factors in hemodialysis patients: A randomized, double-blind, placebo-controlled trial

Akram Kooshki¹, Mohammad Reza Memarzadeh², Mohammad Hassan Rakhshani³, Roya Akbarzadeh⁴, Tahereh Tofighiyan^{5,*}, Elaheh Foroumandi^{1,*}

¹Non-Communicable Diseases Research Center, Department of Nutrition & Biochemistry, School of Medicine, Sabzevar University of Medical Sciences, Sabzevar, Iran

²Barij Medicinal Plants Research Center, Kashan, Iran

³Department of Environmental Health, School of Health, Sabzevar University of Medical Sciences, Sabzevar, Iran

⁴Department of Anesthesiology, Faculty of Paramedical, Sabzevar University of Medical Sciences, Sabzevar, Iran

⁵Department of Nursing, School of Nursing and Midwifery, Sabzevar University of Medical Sciences, Sabzevar, Iran

Article history:

Received: Oct 15, 2022

Received in revised form:

Apr 10, 2023

Accepted: Apr 10, 2023

Epub ahead of print

* Corresponding Author:

Tel: +98-5144018313

Fax: +98-5144018101

Tofighiyan260@gmail.com

Tel: +98-5144018337

Fax: +98-5144018101

elahe.foroumandi@gmail.com

Keywords:

Aloe vera

C-reactive protein

Inflammation

Lipids

Hemodialysis

Abstract

Objective: This study assessed the effects of Aloe vera supplementation on serum inflammatory factors, blood sugar and lipid profiles in hemodialysis patients.

Materials and Methods: Totally, 50 hemodialysis patients were allocated randomly to either Aloe vera or placebo groups. The Aloe vera group received 2 Aloe vera capsules daily for 8 weeks (500 mg/day). Serum C-reactive protein (hs-CRP), Fasting blood glucose (FBS), and lipid profiles levels were evaluated at the baseline and the end of the eighth week.

Results: Aloe vera supplementation for 8 weeks was associated with a significant reduction of serum hs-CRP ($p=0.004$), total cholesterol ($p=0.01$), low density lipoprotein (LDL) ($p=0.02$) levels and increased high density lipoprotein (HDL) ($p=0.002$) concentration in the hemodialysis patients.

Conclusion: Aloe vera supplementation is beneficial in improvement of cardiovascular risk factors in hemodialysis patients.

Please cite this paper as:

Kooshki A, Memarzadeh M.R, Rakhshani M.H, Tofighiyan T, Foroumandi E. Aloe vera supplementation improves cardiovascular risk factors in hemodialysis patients: A randomized, double-blind, placebo-controlled trial. Avicenna J Phytomed, 2023. Epub ahead of print.

Introduction

Chronic hemodialysis patients are at high risks of morbidity and mortality, and they experience a low quality of life (La Russa et al., 2019). Cardiovascular disease

(CVD) is a major cause of death in chronic kidney patients (Jungers et al., 1999). Inflammation, lipid abnormalities, oxidative stress, and hypertension are the major risk factors for CVD in

hemodialysis patients (Jungers *et al.*, 1999). Inflammatory markers such as c-reactive proteins (CRP) and oxidative stress indices increase in chronic kidney disease (CKD) and hemodialysis patients (Yari *et al.*, 2020). Further, lipid abnormalities such as high levels of serum triglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) and low levels of serum high-density lipoprotein cholesterol (HDL-C) are one of the major risk factors for CVDs in these patients (Jungers *et al.*, 1999). HDL-C has multi-protective effects such as vaso-protective and anti-inflammatory actions, which can be impaired in CKD and particularly in hemodialysis patients (Kooshki *et al.*, 2019).

Recently, most of the people have access to variety of traditional medicine and they have tendency to use medicinal plants (Foroumandi *et al.*, 2023). Aloe vera, as a medicinal herb is used for many therapeutic purposes. It is from the Mediterranean region, Arabian Peninsula, India, China, and Eastern Africa (Florens *et al.*, 2019). Aloe vera has a large amount of bioactive compounds such as flavonoids, terpenoids, lectins, fatty acids, anthraquinones, mono saccharides, fibers (pectins, hemicelluloses, and glucomanan), tannins, phytosterols (campesterol, and B-sitosterol), enzymes, salicylic acid, minerals (calcium, chromium, iron, copper, zinc, magnesium, manganese, potassium, phosphorus and sodium), and vitamins (A, B-carotene, C, E, B-complex) (Marzanna *et al.*, 2019). There is evidence that Aloe vera has many medical properties such as lowering blood sugar by improving sensitivity to insulin in diabetic patients (Choudhary *et al.*, 2014; Shahryari *et al.*, 2021), reducing serum TC, triglycerides, and blood pressure and increasing the levels of HDL-C (Vinay *et al.*, 2012). It inhibits cyclooxygenase pathway and reduce prostaglandin E₂ (PGE₂). Also, it contains bradykinin peptidase enzyme which helps breakdown the bradykinin (an inflammatory substance

that causes pain) and decreases the inflammation (Gupta *et al.*, 2017). Further, some recent studies have indicated that Aloe vera can significantly reduce oxidative stress by increasing concentration of glutathione peroxides, superoxide dismutase, phenolic antioxidant (Sahu *et al.*, 2013; Keshavarzi *et al.*, 2014), vitamins A, C, and E and carotenoids (Sahu *et al.*, 2013; Marzanna *et al.*, 2019).

Therefore, this study was the first clinical trial study that was done to demonstrate the effects of Aloe vera supplementation on cardiovascular risk factors in hemodialysis patients.

Materials and Methods

Participant

This study was conducted on the patients who were recruited from the hemodialysis clinic of Vaseii Hospital of the University of Sabzevar, Iran. The study was approved by the Research and Ethical committee of Sabzevar University of Medical Sciences (No: IR.Medsab.Rec.1395.16). Further, the trial was registered in the Iranian website (www.irct.ir) for registration of clinical trials (IRCT code: IRCT20180122038472n3).

Intervention

The inclusion criteria were the patients who were dialyzed with polysulfone capillary dialyzers 3 times a week for 4 hr per session. The subjects who had history of any inflammatory or infectious disorders were excluded. Further, the people who had received Aloe vera, omega-3 fatty acid, L-carnitine, vitamin E and/or C supplements, or steroidal and/or non-steroidal anti-inflammatory drugs were excluded. The hemodialysis procedure and type of the dialyzer were not altered during the study. After explaining the process and objectives of the study to each patient, informed consents were signed by them. Subjects in the Aloe vera group received 2 Aloe vera

capsules (500 mg/day) daily for 8 weeks, while the placebo group received 2 placebo capsules daily. Aloe vera and placebo capsules were prepared by Barij Essence Kashan Company. All the capsules were at the medium size and white color and had a similar appearance. All the researchers and patients were blinded to the type of supplements that were received by the participants.

All participants were advised not to change their lifestyle, diet and physical activity during the study. International physical activity questionnaire (IPAQ) and a 24-hour food recall questionnaire were filled to ensure that these items did not change. The compliance of the patients was assessed according to the number of returned capsules that was more than 90%. No side effects were reported with this supplement.

Blood samples and analyses

Totally, 5 ml blood sample was collected from each patient at the baseline and the end of the study, after a 12 to 14 hr fasting. Blood samples were centrifuged at room temperature (20–25°C) at 2,000 rpm for 10 min. The obtained serum was frozen and kept at –20°C until analyses.

The serum hs-CRP concentration was determined using enzyme-linked immune sorbent assay (ELISA) kits (Monobind, Inc., Lake Forest, Calif., USA). Serum concentrations of FBS, TG, TC, LDL –C, and HDL-C were measured using commercial kits (Pars Azemoon Co., Tehran, Iran), by Hitachi 717 auto-analyzer (Boehringer Mannheim Diagnostics, Mannheim, Germany).

Sample size

The sample size of the study was determined according to formula “ $n = (Z_{1-\alpha/2} + Z_{1-\beta})^2 (\sigma_1^2 + \sigma_2^2) / (\mu_1 - \mu_2)^2$ ”, considering $\alpha=0.05$ and power test of 0.9. Considering Nasab et al, study 46 hemodialysis patients were included in the study using convenience sampling method (Nasab GA et al., 2012).

Statistical analyses

Statistical analysis of the study was performed using SPSS 20 (SPSS, Inc., Chicago, Ill., USA). All the quantitative parameters were normally distributed according to the Shapiro-Wilk test. The differences between investigated risk factors at the baseline and end of the study were analyzed using Paired Sample t-test. Analyses covariance (ANCOVA) was also performed to compare investigated parameters between the groups. The models were further adjusted for a priori selected set of variables including age, sex, body mass index (BMI), and duration of the hemodialysis. A significance level of 0.05 was considered for all analyses.

Results

Totally, 46 patients were participated in the study (Figure 1), as 23 (46%) of them were female and the age range of the patients was 40-75 years. The mean (\pm standard deviation (SD)) age of the patients was 58.2 (\pm 13.5) and 57.05 (\pm 17.7) years in the Aloe vera and placebo groups, respectively. The duration of hemodialysis was 3.3 (\pm 2.7) and 4.5 (\pm 2.9) years in Aloe vera and placebo groups, respectively. The age, gender, duration of disease, and BMI were not significantly different between the groups (Table1).

Fasting blood glucose, lipid profiles, and hs-CRP levels at the baseline of the study and after 8 weeks are presented in Table 2. As seen in Table 2, serum TC ($p=0.01$), LDL-C ($p=0.02$), and hs-CRP ($p=0.004$) status decreased in the Aloe vera group compared to the baseline, while there was not any significant change in the placebo group. Further, the concentration of serum HDL-C in the Aloe vera group was increased compared to the baseline ($p=0.002$).

As seen in Table 3, Aloe vera supplementation was effective in decreasing hs-CRP levels by 10.72 mg/L compared to the placebo group after adjusting the analysis for confounding

factors including sex, age, duration of hemodialysis, BMI, and smoking.




Figure 1. Flowchart of the study

Table 1. Baseline characteristics and anthropometric data of dialysis patients in the Aloe vera and placebo groups

characteristics	Aloe vera (N=23)	Placebo (N=23)
Age (years)	58.26±13.55	57.05±17.70
Duration of diabetes (years)	3.31±2.71	4.58±2.95
sex		
Men, n	17(54.8%)	10(52.6%)
Women, n	14(45.2%)	9(47.4%)
Smoker, n	12(38.7%)	9(47.4%)
BMI (kg/m ²)	25.48±3.73	24.03±6.01

Aloe vera supplementation for hemodialysis patients

Table 2. Serum concentrations of fasting blood glucose (FBG), lipid markers, and hs- CRP in the Aloe vera and placebo group

Serum parameters and groups	Baseline		After 8-week		p-value (within group)	
	Aloe vera	placebo	Aloe vera	placebo	Aloe vera	placebo
FBG (mg/dl)	111.16±7.84	123.00±13.73	132.74±13.19	119.26±11.19	0.07	0.97
Triglyceride (mg/dl)	132.61±21.92	103.74±10.17	101.71±9.92	113.95±15.78	0.11	0.23
Cholesterol (mg/dl)	141.35±5.83	146.26±6.77	128.16±5.83	137.63±7.23	0.01	0.11
LDL-C (mg/dl)	112.90±4.96	119.84±5.30	102.54±4.74	118.74±6.87	0.02	0.34
HDL-C (mg/dl)	38.32±2.30	41.42±2.96	44.45±2.44	46.16±2.97	0.002	0.12
hs-CRP (mg/l)	29.95±3.96	30.83±4.95	18.86±2.51	31.84±5.60	0.004	0.15

Table 3. Comparison of fasting blood glucose (FBG) and serum triglyceride, cholesterol, LDL, HDL, and hs- CRP levels between the Aloe vera group and placebo group

Variable	Model	β	Standard error	Standardized coefficient	%95 CI	p-value
FBG	Crude	-22.82	15.36	-0.17	(-53.72-8.08)	0.14
	Adjusted*	-23.34	15.06	-0.18	(-53.66-6.98)	0.13
Triglyceride	Crude	21.86	15.06	0.18	(-8.43-52.15)	0.15
	Adjusted	24.13	14.82	0.20	(-5.71-53.97)	0.11
Cholesterol	Crude	6.04	6.93	0.09	(-7.90-19.99)	0.39
	Adjusted	9.32	6.81	0.10	(-7.39-20.03)	0.36
LDL-c	Crude	12.39	7.08	0.21	(-1.86-26.61)	0.09
	Adjusted	12.82	7.59	0.22	(-2.49-28.12)	0.10
HDL-c	Crude	-0.41	2.98	0.01	(-6.42-5.59)	0.89
	Adjusted	-0.44	3.05	-0.02	(-6.59-5.71)	0.89
hs-CRP	Crude	9.80	3.71	0.25	(2.33-17.27)	0.011
	Adjusted	10.72	3.94	0.27	(2.78-18.66)	0.010

Discussion

In the current study, 8-weeks of supplementation with Aloe vera was effective in significantly improving serum lipid profiles and hs-CRP in hemodialysis patients. To the best of authors' knowledge, this was the first study that investigated the effects of Aloe vera supplementation on cardiovascular risk factors in hemodialysis patients. In line with the current study, Choudhary *et al.* reported a significant reduction of fasting blood glucose (FBG) and lipid markers, and blood pressure by Aloe vera supplementation among 90 non-insulin

dependent diabetic subjects (Choudhary *et al.*, 2014). Further, Aloe vera gel (two 300 mg capsules a day for 2 months) can effectively reduce FPG, HbA1c, TC, and LDL levels in type 2 diabetic patients with high lipid profiles (Huseini *et al.*, 2011). Furthermore, another study was done on 72 subjects with pre-diabetic symptoms and reported a reduction of FPG, HbA1C, and lipid profile (except HDL) after 8-weeks of Aloe vera supplementation (Alinejad-Mofrad *et al.*, 2015). Inversely, in an animal-based study, oral intake of Aloe vera gel extract for 21 days resulted in a significant reduction of plasma HDL-c

levels and increased plasma status of LDL-c and VLDL-c in diabetic rats (Rajasekaran *et al.*, 2006). Indeed, another study revealed that Aloe vera supplementation has no significant effect on blood glucose levels and lipid profile in diabetes mellitus type 2 patients (Zarrintan *et al.*, 2015). It can be suggested that Aloe vera has a high amount of Acemannan that can efficiently improve the blood lipid profile through the expression of genes that are responsible for fatty acids metabolism in liver. Also, the compounds in Aloe vera with the help of intestinal bacteria prevent the absorption of sugar and fat compounds from the intestine and improve the lipid profile (Yazdani *et al.*, 2017).

High consumption of Aloe vera caused nephrotoxicity including renal tubular damage, papillary necrosis, and nephrolithiasis, occurred by high dose of plant (Luyckx *et al.*, 2002). There is need for further clinical trials to investigate the exact effects of Aloe vera on CVD risk factors and discover the safe dose for this plant in the hemodialysis patients.

In current study, intake of Aloe vera was effective in reduction of serum hs-CRP. Observational studies have shown positive associations between inflammatory mediators and hemodialysis dependency (Kooshki *et al.*, 2019). The results of current study were in line with the results of Devarai *et al.* that was conducted on metabolic syndrome patients and showed a reduction of hs-CRP by oral intake of Aloe vera (Devaraj *et al.*, 2013). Further, the same result was revealed in male rabbits (Dana *et al.*, 2012).

Aloe vera, as a traditional herbal medicine contains over 70 biologically active compounds. Many studies have been conducted on the properties of this amazing substance and it can be stated that the intake of Aloe vera has anti-inflammatory and anti-oxidant properties that can increase the body's immunity (Langmead *et al.*, 2004). The immunity boosting of Aloe vera may be caused

thorough inhibition of reactive oxygen metabolites, prostaglandins, and interleukin-8 production (Langmead *et al.*, 2004). Further, Aloe vera can effectively express ATP sensor P2X7 receptor and attenuate IL-1 β cytokine secretion (Budai *et al.*, 2013). Furthermore, Aloe vera is effective in reduction of tumor necrosis factor alpha and raising interleukin-10, while it had no effect on the cyclooxygenase-2 (COX2) and prostaglandin E2 (PGE2) levels (Keshavarzi *et al.*, 2021). Also, another study indicated that the carbohydrate fraction of Aloe vera can scavenge free radicals and prevent cell membrane lysis. This process can reduce the inflammatory mediators with an increase in antioxidant enzymes such as superoxide dismutase (SOD) and catalase enzymes (Govindarajan *et al.*, 2021).

The limitation of the study was lack of assessment of the effect of Aloe vera supplementation on vascular inflammation markers and apo-lipoproteins. Therefore, further studies in clinical settings should assess these effects and the involved mechanisms.

Our findings justify the role of Aloe vera in reduction of the serum lipid profiles and hs-CRP, as the risk factors of CVD in hemodialysis patients. The study suggests that Aloe vera supplementation might be useful as a complementary therapy along with the usual treatments for the management of cardiovascular complications in hemodialysis patients.

Acknowledgment

This study was supported by Sabzevar University of Medical sciences, Sabzevar, Iran. The authors thank the staff of Hemodialysis Unit of Vaseii Hospital in Sabzevar city for their valuable assistance; the authors also gratefully acknowledge the co-operation of the participating patients, without whom this investigation would not have been possible.

Conflicts of interest

The authors have declared that there is no conflict of interest. We also declared no financial or other conflict with Barij Essence Kashan Company.

References

- Alinejad-Mofrad S, Foadoddini M, Saadatjoo SA, Shayesteh M. 2015. Improvement of glucose and lipid profile status with Aloe vera in pre-diabetic subjects: a randomized controlled-trial. *J Diabetes Metab Disord*, 14: 22-25.
- Budai MM1, Varga A, Milesz S, Tózsér J, Benkő S. 2013. Aloe vera downregulates LPS-induced inflammatory cytokine production and expression of NLRP3 inflammasome in human macrophages. *Mol Immunol*, 56: 471-479.
- Choudhary M, Kochhar A, Sangha J. 2014. Hypoglycemic and hypolipidemic effect of Aloe vera L. in non-insulin dependent diabetics. *J Food Sci Technol*, 51: 90-96.
- Dana N, Haghjooy Javanmard Sh, Asgary S, Asnaashari H, Abdian N. 2012. The effect of Aloe vera leaf gel on fatty streak formation in hypercholesterolemic rabbits. *J Res Med Sci*, 1: 439-442.
- Devaraj S, Yimam M, Brownell LA, Jialal I, Singh S, Jia Q. 2013. Effects of Aloe vera supplementation in subjects with prediabetes/metabolic syndrome. *Metab Syndr Relat Disord*, 11: 35-40.
- Florens N, Calzada C, Delolme F, Page A, Egziabher F, Juillard L, Christophe O. 2019. Proteomic characterization of high-density lipoprotein particles from non-diabetic hemodialysis patients. *Toxins*, 11: 671-674.
- Foroumandi E, Javan R, Moayed L, Fahimi H, Kheirabadi F, Neamatshahi M, Shogofteh F, Zarghi A. 2023. The effects of fenugreek seed extract supplementation in patients with Alzheimer's disease: A randomized, double-blind, placebo-controlled trial. *Phytother Re*, 37: 285-294.
- Govindarajan S, Noor A. 2021. Carbohydrate fraction of Aloe vera ameliorates inflammation through suppression of pro-inflammatory mediators and oxidative stress *in vitro* and rats with Freund's adjuvant induced paw edema. *Indian J Exp Biol*, 59: 177-185.
- Gupta A, Rawat S. 2017. Clinical importance of Aloe vera: review. *Res J Top Cosmet Sci*, 8: 30-39.
- Huseini HF, Kianbakht S, Hajiaghvae R, Dabaghian FH. 2012. Anti-hyperglycemic and anti-hypercholesterolemic effects of Aloe vera leaf gel in hyperlipidemic type 2 diabetic patients: a randomized double-blind placebo-controlled clinical trial. *Planta Med*, 78: 311-316.
- Jungers P, Nguyen Khoa T, Massy ZA. 1999. Incidence of atherosclerotic arterial occlusive accidents in predialysis and dialysis patients: A study in the Ile de France district. *Nephrol Dial Transplant*, 14: 898-902.
- Keshavarzi Z, Hadjzadeh M, Masoud Nazari M, Arezumand R. 2021. Protective effect of Aloe vera gel in ulcerative colitis: The role of inflammatory and anti-inflammatory factors. *Sci J Kurd Univ Med Sci*, 114: 69-79. [In Persian]
- Keshavarzi Z, Rezapour TM, Vatanchian M, Hesari MZ, Haghghi HN, Izanlu M, Sabaghian M, Shahveisi K. 2014. The effects of aqueous extract of Aloe vera leaves on the gastric acid secretion and brain and intestinal water content following acetic acid-induced gastric ulcer in male rats. *Avicenna J Phytomed*, 4: 137-139.
- kooshki A, Tofighiyan T, Miri M. 2019. A synbiotic supplement for inflammation and oxidative stress and lipid abnormalities in hemodialysis patients. *Hemodial Int*, 10: 254-260.
- Langmead L, Makins RJ, Rampton DS. 2004. Anti-inflammatory effects of aloe vera gel in human colorectal mucosa *in vitro*. *Aliment Pharmacol Ther*, 19: 521-527.
- La Russa D, Pellegrino D, Montesanto A, Gigliotti P, Perri A, La Russa A, Bonofiglio R. 2019. Oxidative balance and inflammation in hemodialysis patients: Biomarkers of cardiovascular risk? *Oxid Med Cell Longev*, 2019: 8567275.
- Luyckx VA, Ballantine R, Claeys M, Cuyckens F, Van den Heuvel H, Cimanga RK. 2002. Herbal remedy-associated acute renal failure secondary to Cape aloes. *Am J Kidney Dis*, 39: 13-18.
- Marzanna H, Krzysztow D, Danuta G,

- Jędrusek-Golińska A, Gujska E. 2019. Aloe vera: Natural sources of antioxidants – A Review. *Plant Foods Hum Nutr*, 74: 255-265.
- Nasab GA, Delavar R, Taheri H. 2021. The effect of combined exercise course and aloe-vera supplementation on renal function and lipid profile in type 2 diabetes mellitus patients: A randomized clinical trial. *Iran J Diabetes Obes*, 15: 20-23.
- Rajasekaran S, Ravi K, Sivagnanam K, Subramanian S. 2006. Beneficial effects of aloe vera leaf gel extract on lipid profile status in rats with streptozotocin diabetes. *Clin Exp Pharmacol Physiol*, 33: 232-237.
- Sahu PK, Giri DD, Singh R. 2013. Therapeutic uses of Aloe vera: a review. *Pharmacol Amp Pharm*, 4: 599-610.
- Shahryari M, Bibak B, Khaksari M, Keshavarzi Z, Salmani N, Shirazpour S, Alimahdi F. 2021. Anti-edema effect of Aloe vera leaf extract following traumatic brain injury: Role of pro-inflammatory cytokines. *Avicenna J Phytomed*, 11: 380-381.
- Vinay KG, Seema M. 2012. Pharmacological attribute of Aloe vera: Revalidation through experimental and clinical studies. *Ayu*, 33: 193-196.
- Yari Z, Tabibi H, Najafi I, Hedayati M, Movahedian M. 2020. Effects of soy isoflavones on serum lipids and lipoprotein (a) in peritoneal dialysis patients. *Nutr Metab Cardiovasc Dis*, 30: 1382-1388.
- Yazdani N, Hosseini SE. 2017. Hypolipidemic effects of aloe-vera gel extract on adult male rats under high-fat diet. *J Ardabil Univ Med Sci*, 17: 375-382. [in Persian]
- Zarrintan A, Mobasseri M, Zarrintan A, Ostadrahimi A. 2015. Effects of aloe vera supplements on blood glucose level and lipid profile markers in type 2 diabetic patients – A randomized clinical trial. *Pharm Sci*, 21: 65-67.